| Literature DB >> 24676368 |
José Sebastião de Abreu1, José Wellington Oliveira Lima2, Tereza Cristina Pinheiro Diógenes1, Jordana Magalhães Siqueira3, Nayara Lima Pimentel3, Pedro Sabino Gomes Neto3, Marília Esther Benevides de Abreu1, José Nogueira Paes Júnior1.
Abstract
BACKGROUND: A coronary flow velocity reserve (CFVR)≥2 is adequate to infer a favorable prognosis or the absence of significant coronary artery disease.Entities:
Mesh:
Year: 2013 PMID: 24676368 PMCID: PMC3987342 DOI: 10.5935/abc.20130242
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Figure 1Diastolic peak velocity (DPV), coronary flow velocity reserve (CFVR) and correlated heart rate (HR). Group I: DPV= 45cm/s and HR= 65bpm at rest (A) with DPV= 77cm/s and HR= 139bpm during stress (B), determining CFVR= 1.71 after achieving the target HR (138). Group II: DPV= 34cm/s and HR= 90bpm at rest (C) with DPV = 89cm/s and HR= 137bpm during stress (D), determining CFVR= 2.61 after achieving the target HR (131).
Figure 2CFVR = 3 was obtained early (HR= 118bpm) in relation to the target HR (140bpm).
Characteristics of a sample (N=92) of patients undergoing dobutamine stress echocardiography, according to the category of coronary flow velocity reserve (CFVR)
|
| ||||
|
|
| |||
| Male | 53 | 14 (45) | 39(65) | 0.07 |
| Female | 39 | 18 (46) | 21 (54) | |
| Hypertension | ||||
| - Absent | 26 | 6 (23) | 20(77) | |
| - Present | 66 | 26 (39.4) | 40 (60.6) | |
| Dyslipidemia | ||||
| - Absent | 33 | 12 (36.4) | 21 (63.6) | |
| - Present | 59 | 20 (34) | 39(66) | |
| Diabetes | ||||
| - Absent | 75 | 26 (34.7) | 49 (65.3) | |
| - Present | 17 | 6(35.3) | 11 (64.7) | |
| Use of ASA | ||||
| - No | 59 | 16 (27) | 43(73) | |
| - Yes | 33 | 16 (48.5) | 17 (51.5) | |
| Use of Statin | ||||
| - No | 49 | 17 (34.7) | 32 (65.3) | |
| - Yes | 43 | 15 (35) | 28(65) | |
| Use of ACE or ARA Inhibitor | 1.000 | |||
| - No | 45 | 16 (35.6) | 29 (64.4) | |
| - Yes | 47 | 16 (34) | 31 (66) | |
| Use of Nitrate | ||||
| - No | 86 | 29 (34) | 57(66) | |
| - Yes | 6 | 3 (50) | 3 (50) | |
| Betablocker | ||||
| - Did not take or did not discontinue | 70 | 18 (26) | 52(74) | |
| - Discontinued | 22 | 14 (64) | 8 (36) | |
| History of CAD | ||||
| - Absent | 67 | 20 (30) | 47(70) | |
| - Present | 25 | 12 (48) | 13 (52) | |
| Previous CI | ||||
| - Absent | 72 | 24 (33) | 48(67) | |
| - Present | 20 | 8 (40) | 12 (60) | |
| Previous IM | ||||
| - Absent | 87 | 31 (35.6) | 56 (64.4) | |
| - Present | 5 | 1 (20) | 4 (80) | |
ASA: Acetyl salicylic acid; ACE: Angiotensin converting enzyme; ARA: Angiotensin receptor antagonist; CAD: Coronary artery disease; CI: Coronary intervention; MI: Myocardial infarction.
Echocardiographic and hemodynamic recordings, according to categories (Groups I and II) of coronary flow velocity reserve
|
|
|
|
| |||
|
|
|
|
| |||
| Left ventricle | ||||||
| Ejection fraction (%) | 61 | 1.8 | 65.8 | 0.7 | 0.005 | |
| Mass (gr) | 250.5 | 17.5 | 232.4 | 8.9 | 0.30 | |
| Mass / BS (gr/m2) | 142.5 | 9.2 | 128.5 | 4.7 | 0.13 | |
| Heart rate (bpm) | ||||||
| Baseline | 72 | 2.3 | 67 | 1.4 | 0.058 | |
| During DSE | 141 | 3.5 | 148 | 1.5 | 0.04 | |
| Blood pressure (mmHg) | ||||||
| Systolic (Baseline) | 131 | 3.3 | 126 | 1.8 | 0.17 | |
| Systolic (DSE) | 151 | 3.1 | 152 | 2.1 | 0.08 | |
| Diastolic (Baseline) | 78 | 1.3 | 78 | 0.8 | 0.85 | |
| Diastolic (DSE) | 83 | 1.7 | 80 | 1.2 | 0.25 | |
| Double Product (mmHg x bpm) during DSE | 21263 | 685 | 22423 | 380 | 0.11 | |
BS: Body surface; DSE: Dobutamine stress echocardiography; Double product: systolic blood pressure x heart rate.
Measurements obtained during Doppler in the anterior descending coronary artery
|
|
|
| |||
|
|
|
|
| ||
| Tempo (segundos) para obter o Doppler na ADA | 53 | 5.5 | 45 | 4.1 | 0.23 |
| FC ao registrar PVD | |||||
| Basal (bpm) | 72 | 2.3 | 67 | 1.4 | 0.058 |
| Durante o EED (bpm) | 123 | 5.0 | 119 | 2.7 | 0.47 |
| PVD (cm/s) Basal | 36.8 | 0.014 | 25.6 | 0.07 | < 0.0001 |
| PVD (cm/s) no EED | 61.4 | 0.029 | 64.2 | 0.020 | 0.42 |
| RVFC(PVD no EED÷PVD basal) | 1.67 | 0.042 | 2.53 | 0.073 | < 0.0001 |
LAD: Left anterior descending coronary artery; HR: heart rate, DPV: Diastolic peak velocity; DSE: Dobutamine stress echocardiography; CFVR: Coronary flow velocity reserve.
Multivariate logistic regression analysis for CFVR < 2
|
|
|
|
| |
|
|
| |||
| Age | 1.053882 | 0.037 | 1.003145 | 1.107185 |
| Ejection F. | 0.9426074 | 1.181 | 0.8644104 | 1.027878 |
| LV Mass /BS | 1.004491 | 0.517 | 0.9909688 | 1.018197 |
| Betablocker | 3.997332 | 0.027 | 1.17166 | 13.63763 |
| ASA | 1.460583 | 0.598 | 0.3569187 | 5.976994 |
| SH | 1.07366 | 0.913 | 0.3009711 | 3.830089 |
| CAD | 0.778762 | 0.747 | 0.1709659 | 3.547317 |
OR: Odds ratio; CI: Confidence interval; LL: Lower limit; UL: Upper limit; LV Mass/BS: left ventricular mass indexed for body surface; ASA: acetyl salicylic acid; SH: systemic hypertension; CAD: coronary artery disease.
Multivariate models of the relationship between variables and coronary flow velocity reserve as measured by dobutamine stress echocardiography
|
|
|
|
|
|
| Betablocker | 5.05 | 2.6 | 1.82 - 14.03 | 0.002 |
| Betablocker | 3.9 | 2.5 | 1.17 - 13.64 | 0.027 |
| Betablocker | 4.17 | 2.4 | 1.35 - 12.82 | 0.013 |
Modelo não ajustado.
Modelo completo, ajustado para idade, fração de ejeção, massa do ventrículo esquerdo/superfície corporal, uso de AAS, hipertensão arterial, doença arterial coronariana.
Modelo ajustado para idade e fração de ejeção. As demais variáveis, quando retiradas do modelo completo, modificaram o OR em menos de 10%.